Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1235-1243

  Sturla, L M ^a,b   Zinn, P O ^a,b   Ng, K ^b   Nitta, M ^b,c   Kozono, D ^b   Chen, C C ^a,b   Kasper, E M ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

glioblastoma; phosphatases; senescence; SHP2

Indexed keywords

BETA GALACTOSIDASE; DNA NUCLEOTIDYLEXOTRANSFERASE; PROPIDIUM IODIDE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CELL AGING; CELL VIABILITY; CONTROLLED STUDY; ENZYME ANALYSIS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; PRIORITY JOURNAL; STAINING;

BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; IN SITU NICK-END LABELING; MUTATION; PRINCIPAL COMPONENT ANALYSIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; RNA, SMALL INTERFERING;

EID: 80053938400     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.345     Document Type: Article

References (33)

1. Agazie YM, Hayman MJ (2003) Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol Cell Biol 23: 7875-7886 (Pubitemid 37271483)
2. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG (2004) Activating mutations of the Noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 64: 8816-8820 (Pubitemid 39665483)
3. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, Aldape KD, Chakravarti A, Harsh GR (2010) NFKBIA deletion in glioblastomas. N Engl J Med 364: 627-637
4. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710 (Pubitemid 350070717)
5. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncology 7: 164-176 (Pubitemid 40590516)
6. Grossmann KS, Rosario M, Birchmeier C, Birchmeier W (2010) The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 106: 53-89
7. Haque SJ, Flati V, Deb A, Williams BR (1995) Roles of protein-tyrosine phosphatases in Stat1 alpha-mediated cell signaling. J Biol Chem 270: 25709-25714
8. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE (1998) Crystal structure of the tyrosine phosphatase SHP-2. Cell 92: 441-450 (Pubitemid 28101108)
9. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H, Nijkamp W, Xie J, Callens T, Asgharzadeh S, Seeger RC, Messiaen L, Versteeg R, Bernards R (2010) NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 142: 218-229
10. Jakob S, Schroder P, Lucosz M, Spyridopoulos I, Altschmeid J, Haendler J (2008) Nuclear protein tyrosine phosphatase Shp-2 is one important negative regulator of nuclear export of telomerase reverse transcriptase. J Biol Chem 283: 33155-33161
11. Keilhack H, David FS, McGregor M, Cantley LC, Neel BG (2005) Diverse biochemical properties of Shp2 mutants: implications for disease phenotypes. J Biol Chem 280(35): 30984-30993 (Pubitemid 41291831)
12. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011-2015
13. Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J (2011) Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type-and insult-dependent manner, and follow expression of p16 (ink4a). Cell Cycle 10: 457-468
14. Milenkovic I, Weick M, Wiedemann P, Reichenbach A, Bringmann A (2003) P2Y receptor-mediated stimulation of Muller glial cell DNA synthesis: dependence on EGF and PDGF receptor transactivation. Invest Ophthalmol Vis Sci 44: 1211-1220 (Pubitemid 36297842)
15. Network CGAR (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068
16. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz Jr LA, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY) 321: 1807-1812
17. Quick QA, Gewirtz DA (2006) An accelerated senescence response to radiation in wild-type p53 glioblastoma multiforme cells. J Neurosurg 105: 111-118 (Pubitemid 43979105)
18. Rai P, Young JJ, Burton DG, Giribaldi MG, Onder TT, Weinberg RA (2010) Enhanced elimination of oxidized guanine nucleotides inhibits oncogenic RAS-induced DNA damage and premature senescence. Oncogene 30: 1489-1496
19. Reynolds AR, Tischer C, Verveer PJ, Rocks O, Bastiaens PI (2003) EGFR activation coupled to inhibition of tyrosine phosphatases causes lateral signal propagation. Nat Cell Biol 5: 447-453 (Pubitemid 36592268)
20. Rich JN, Guo C, McLendon RE, Bigner DD, Wang XF, Counter CM (2001) A genetically tractable model of human glioma formation. Cancer Res 61: 3556-3560 (Pubitemid 32694959)
21. Sano T, Asai A, Mishima K, Fujimaki T, Kirino T (1998) Telomerase activity in 144 brain tumours. Br J Cancer 77: 1633-1637 (Pubitemid 28230464)
22. Schmidt-Ullrich RK, Contessa JN, Lammering G, Amorino G, Lin PS (2003) ERBB receptor tyrosine kinases and cellular radiation responses. Oncogene 22: 5855-5865 (Pubitemid 37176706)
23. Shimizu M, Shirakami Y, Moriwaki H (2008) Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG. Int J Mol Sci 9: 1034-1049 (Pubitemid 351948839)
24. Sonoda Y, Ozawa T, Hirose Y, Aldape KD, McMahon M, Berger MS, Pieper RO (2001) Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. Cancer Res 61: 4956-4960 (Pubitemid 32681517)
25. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996 (Pubitemid 40349501)
26. Sturla LM, Amorino G, Alexander MS, Mikkelsen RB, Valerie K, Schmidt-Ullrichr RK (2005) Requirement of Tyr-992 and Tyr-1173 in phosphorylation of the epidermal growth factor receptor by ionizing radiation and modulation by SHP2. J Biol Chem 280: 14597-14604 (Pubitemid 40562804)
27. Sun X, Mei S, Tao H, Wang G, Su L, Jiang S, Deng C, Xiong Y, Li F (2011) Microarray profiling for differential gene expression in PMSG-hCG stimulated preovulatory ovarian follicles of Chinese Taihu and Large White sows. BMC Genom 12: 111
28. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes DN (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110
29. Wang V, Davis DA, Veeranna RP, Haque M, Yarchoan R (2010) Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha. PLoS One 5: e9641
30. Wu CJ, Chen Z, Ullrich A, Greene MI, O'Rourke DM (2000) Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs). Oncogene 19: 3999-4010
31. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773
32. Zhan Y, Counelis GJ, O'Rourke DM (2009) The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells. Exp Cell Res 315: 2343-2357
33. Zhang W, Chan RJ, Chen H, Yang Z, He Y, Zhang X, Luo Y, Yin F, Moh A, Miller LC, Payne RM, Zhang ZY, Fu XY, Shou W (2009) Negative regulation of Stat3 by activating PTPN11 mutants contributes to the pathogenesis of Noonan syndrome and juvenile myelomonocytic leukemia. J Biol Chem 284: 22353-22363